



October 12, 2016

## **TG Therapeutics, Inc. to Host Conference Call to Provide an Update on the GENUINE Phase 3 Trial**

### **Investor Conference Call to be held tomorrow, Thursday, October 13, 2016 at 8:30am ET**

NEW YORK, Oct. 12, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held tomorrow, Thursday, October 13, 2016 at 8:30am ET to provide an update on the GENUINE Phase 3 Trial. Michael S. Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.

In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics GENUINE Update Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at [www.tgtherapeutics.com](http://www.tgtherapeutics.com). An audio recording of the conference call will also be available for replay at [www.tgtherapeutics.com](http://www.tgtherapeutics.com), for a period of 30 days after the call.

TG Therapeutics will announce details of the amendments in a press release to be issued prior to the call.

### **ABOUT TG THERAPEUTICS, INC.**

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublrituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 recently entering clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.

TGTX - G

CONTACT:

Jenna Bosco

Vice President- Investor Relations

TG Therapeutics, Inc.

Telephone: 212.554.4351

Email: [ir@tgtxinc.com](mailto:ir@tgtxinc.com)

Primary Logo

Source: TG Therapeutics, Inc.

News Provided by Acquire Media